Boulder’s Inscripta buys Solana Biosciences
BOULDER — Inscripta Inc., a gene-editing technology company based in Boulder, has purchased Solana Biosciences Inc., a life-sciences company founded by veterans of Illumina Inc. (Nasdaq: ILMN). Inscripta and Solana have joined forces to accelerate the commercialization of Inscripta’s suite of gene-editing technology tools. Inscripta’s acquisition of Solana assembles a life-sciences product development and manufacturing pipeline for precision gene editing.
Inscripta is advancing genomic research by providing CRISPR-based genome-editing and tracking technologies to researchers, allowing genome editing of living cells to be simple and efficient. The company has also developed a family of CRISPR enzymes (MADzymes)…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
